Dolutegravir for second-line antiretroviral therapy: the beat goes on

Lancet Glob Health. 2024 Feb;12(2):e183-e184. doi: 10.1016/S2214-109X(23)00569-7. Epub 2023 Dec 21.

Authors

Nosipho Shangase¹, Tendesayi Kufa²

Affiliations

¹ National Institute for Communicable Diseases, Sandringham Johannesburg, 2131, South Africa.
² National Institute for Communicable Diseases, Sandringham Johannesburg, 2131, South Africa; School of Public Health, University of the Witwatersrand, Johannesburg, South Africa. Electronic address: tendesayikc@nicd.ac.za.

PMID: 38142693
DOI: 10.1016/S2214-109X(23)00569-7

No abstract available

MeSH terms

Anti-HIV Agents* / therapeutic use
Anti-Retroviral Agents / therapeutic use
HIV Infections* / drug therapy
Heterocyclic Compounds, 3-Ring / therapeutic use
Humans
Oxazines / therapeutic use
Piperazines*
Pyridones*
Viral Load

Substances

dolutegravir
Oxazines
Anti-Retroviral Agents
Heterocyclic Compounds, 3-Ring
Anti-HIV Agents
Piperazines
Pyridones